BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tang S, Lai FM, Lui YH, Tang CS, Kung NN, Ho YW, Chan KW, Leung JC, Lai KN. Lamivudine in hepatitis B-associated membranous nephropathy. Kidney Int 2005;68:1750-8. [PMID: 16164651 DOI: 10.1111/j.1523-1755.2005.00591.x] [Cited by in Crossref: 88] [Cited by in F6Publishing: 65] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Fu B, Ji Y, Hu S, Ren T, Bhuva MS, Li G, Yang H. Efficacy and safety of anti-viral therapy for Hepatitis B virus-associated glomerulonephritis: A meta-analysis. PLoS One 2020;15:e0227532. [PMID: 31940324 DOI: 10.1371/journal.pone.0227532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Yang Y, Ma YP, Chen DP, Zhuo L, Li WG. A Meta-Analysis of Antiviral Therapy for Hepatitis B Virus-Associated Membranous Nephropathy. PLoS One 2016;11:e0160437. [PMID: 27598699 DOI: 10.1371/journal.pone.0160437] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
3 Ikee R, Ishioka K, Oka M, Maesato K, Moriya H, Hidaka S, Ohtake T, Kobayashi S. Hepatitis B virus-related membranous nephropathy treated with entecavir. Nephrology (Carlton). 2010;15:266. [PMID: 20470290 DOI: 10.1111/j.1440-1797.2009.01165.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
4 Deegens JK, Wetzels JF. Membranous nephropathy in the older adult: epidemiology, diagnosis and management. Drugs Aging 2007;24:717-32. [PMID: 17727303 DOI: 10.2165/00002512-200724090-00002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
5 Yan Z, Qiao B, Zhang H, Wang Y, Gou W. Effectiveness of telbivudine antiviral treatment in patients with hepatitis B virus-associated glomerulonephritis: A 104-week pilot study. Medicine (Baltimore) 2018;97:e11716. [PMID: 30075577 DOI: 10.1097/MD.0000000000011716] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
6 Yi Z, Wei Jie Y, Nan Z. The efficacy of anti-viral therapy on hepatitis B virus-associated glomerulonephritis: A systematic review and meta-analysis. Annals of Hepatology 2011;10:165-73. [DOI: 10.1016/s1665-2681(19)31565-0] [Cited by in Crossref: 39] [Article Influence: 3.9] [Reference Citation Analysis]
7 Li H, Yuan X, Qiu L, Zhou Q, Xiao P. Efficacy of adefovir dipivoxil combined with a corticosteroid in 38 cases of nephrotic syndrome induced by hepatitis B virus-associated glomerulonephritis. Ren Fail 2014;36:1404-6. [PMID: 25246340 DOI: 10.3109/0886022X.2014.952745] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
8 Elewa U, Sandri AM, Kim WR, Fervenza FC. Treatment of hepatitis B virus-associated nephropathy. Nephron Clin Pract 2011;119:c41-9; discussion c49. [PMID: 21677438 DOI: 10.1159/000324652] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
9 Zignego AL, Piluso A, Giannini C. HBV and HCV chronic infection: autoimmune manifestations and lymphoproliferation. Autoimmun Rev. 2008;8:107-111. [PMID: 18700171 DOI: 10.1016/j.autrev.2008.07.012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
10 Lee M, Oh S, Lee HJ, Yeum TS, Lee JH, Yu SJ, Kim HY, Yoon JH, Lee HS, Kim YJ. Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy. J Viral Hepat. 2014;21:873-881. [PMID: 24351112 DOI: 10.1111/jvh.12217] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
11 Xu G, Huang T. Hepatitis B virus-associated glomerular nephritis in East Asia: progress and challenges. Eur J Intern Med 2011;22:161-6. [PMID: 21402246 DOI: 10.1016/j.ejim.2010.11.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
12 Yang Y, Xiong Q, Zhao W, Zhong Y. Complete remission of hepatitis B virus-related membranous nephropathy after entecavir monotherapy. Clinics and Research in Hepatology and Gastroenterology 2012;36:e89-92. [DOI: 10.1016/j.clinre.2012.03.033] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
13 Coffin CS, Fung SK, Ma MM; Canadian Association for the Study of the Liver. Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines. Can J Gastroenterol 2012;26:917-38. [PMID: 23248795 DOI: 10.1155/2012/506819] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 4.8] [Reference Citation Analysis]
14 Zhang Y, Li J, Peng W, Yu G, Wang L, Chen J, Zheng F. HBV-Associated Postinfectious Acute Glomerulonephritis: A Report of 10 Cases. PLoS One 2016;11:e0160626. [PMID: 27512989 DOI: 10.1371/journal.pone.0160626] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
15 Zheng XY, Wei RB, Tang L, Li P, Zheng XD. Meta-analysis of combined therapy for adult hepatitis B virus-associated glomerulonephritis. World J Gastroenterol 2012; 18(8): 821-832 [PMID: 22371643 DOI: 10.3748/wjg.v18.i8.821] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
16 Naicker S, Fabian J, Naidoo S, Wadee S, Paget G, Goetsch S. Infection and glomerulonephritis. Semin Immunopathol 2007;29:397-414. [PMID: 17846774 DOI: 10.1007/s00281-007-0088-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
17 Ishizaka N, Ishizaka Y, Seki G, Nagai R, Yamakado M, Koike K. Association between hepatitis BC viral infection, chronic kidney disease and insulin resistance in individuals undergoing general health screening. Hepatology Research 2008;38:775-83. [DOI: 10.1111/j.1872-034x.2008.00334.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
18 Holt SG, Gracey DM, Levy MT, Mudge DW, Irish AB, Walker RG, Baer R, Sevastos J, Abbas R, Boyd MA. A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection. AIDS Res Ther 2014;11:35. [PMID: 25745499 DOI: 10.1186/1742-6405-11-35] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
19 Hamid CK, Hameed RA, Khaliq BI, Manzoor R, Hamid CQ. HIV associated lupus like nephropathy. Ethiop J Health Sci 2014;24:277-83. [PMID: 25183936 DOI: 10.4314/ejhs.v24i3.13] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
20 Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98. [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4] [Cited by in Crossref: 1076] [Cited by in F6Publishing: 1008] [Article Influence: 179.3] [Reference Citation Analysis]
21 Das P, Vivek V, Ford M, Kingdon E, Holt S. Hepatitis B virus related membranous glomerulonephritis and proteinuria treated with lamivudine and tenofovir. BMJ Case Rep 2011;2011:bcr0520114287. [PMID: 22679045 DOI: 10.1136/bcr.05.2011.4287] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
22 Mauss S, Berger F, Filmann N, Hueppe D, Henke J, Hegener P, Athmann C, Schmutz G, Herrmann E. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J Hepatol. 2011;55:1235-1240. [PMID: 21703180 DOI: 10.1016/j.jhep.2011.03.030] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 6.4] [Reference Citation Analysis]
23 Trépo C, Amiri M, Guillevin L. Extrahepatic Manifestations of Hepatitis B Infection. In: Thomas HC, Lok AS, Locarnini SA, Zuckerman AJ, editors. Viral Hepatitis. Oxford: John Wiley & Sons, Ltd; 2013. pp. 154-62. [DOI: 10.1002/9781118637272.ch11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
24 Pipili CL, Papatheodoridis GV, Cholongitas EC. Treatment of hepatitis B in patients with chronic kidney disease. Kidney Int. 2013;84:880-885. [PMID: 23783238 DOI: 10.1038/ki.2013.249] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
25 Wang D, Yan X, Zhang M, Ren C, Wang L, Ma J, Guo L. Association between liver cirrhosis and estimated glomerular filtration rates in patients with chronic HBV infection. Medicine (Baltimore) 2020;99:e21387. [PMID: 32871988 DOI: 10.1097/MD.0000000000021387] [Reference Citation Analysis]
26 Di Marco V, De Lisi S, Li Vecchi M, Maringhini S, Barbaria F. Therapy with lamivudine and steroids in a patient with acute hepatitis B and rapidly progressive glomerulonephritis. Kidney International 2006;70:1187-8. [DOI: 10.1038/sj.ki.5001668] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
27 Karie S, Launay-vacher V, Deray G, Isnard-bagnis C. Toxicité rénale des médicaments. Néphrologie & Thérapeutique 2010;6:58-74. [DOI: 10.1016/j.nephro.2009.02.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
28 Izzedine H, Massard J, Poynard T, Deray G. Lamivudine and HBV-associated nephropathy. Nephrol Dial Transplant. 2006;21:828-829. [PMID: 16263733 DOI: 10.1093/ndt/gfi239] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
29 Pipili C, Cholongitas E, Papatheodoridis G. Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease. Aliment Pharmacol Ther. 2014;39:35-46. [PMID: 24299322 DOI: 10.1111/apt.12538] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
30 熊清芳, 杨永峰. HBV相关性肾炎的抗病毒治疗. 世界华人消化杂志 2011; 19(15): 1620-1623 [DOI: 10.11569/wcjd.v19.i15.1620] [Reference Citation Analysis]
31 Liu Y, Shi C, Fan J, Wang B, Li G. Hepatitis B-related glomerulonephritis and optimization of treatment. Expert Rev Gastroenterol Hepatol 2020;14:113-25. [PMID: 31951758 DOI: 10.1080/17474124.2020.1717948] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Zhang Y, Zhou JH, Yin XL, Wang FY. Treatment of hepatitis B virus-associated glomerulonephritis: A meta-analysis. World J Gastroenterol 2010; 16(6): 770-777 [PMID: 20135728 DOI: 10.3748/wjg.v16.i6.770] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
33 杨道坤, 孙屹峰, 梁海军, 申保生, 乔汉臣. 复方甘草酸苷联合拉米夫定治疗乙型肝炎相关性肾炎40例. 世界华人消化杂志 2010; 18(13): 1380-1383 [DOI: 10.11569/wcjd.v18.i13.1380] [Reference Citation Analysis]
34 Sampaio MS, Martin P, Bunnapradist S. Renal dysfunction in end-stage liver disease and post-liver transplant. Clin Liver Dis 2014;18:543-60. [PMID: 25017075 DOI: 10.1016/j.cld.2014.05.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
35 Peters MG. Special populations with hepatitis B virus infection. Hepatology. 2009;49:S146-S155. [PMID: 19399810 DOI: 10.1002/hep.22965] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
36 Sun IO, Hong YA, Park HS, Choi SR, Chung BH, Park CW, Yang CW, Kim YS, Choi BS. Experience of anti-viral therapy in hepatitis B-associated membranous nephropathy, including Lamivudine-resistant strains. Korean J Intern Med 2012;27:411-6. [PMID: 23269882 DOI: 10.3904/kjim.2012.27.4.411] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
37 Lei X, Gao X, Yang J, Sun Y, Sai Y, You W, Yuan H. The genotype C could play a key role in hepatitis B virus associated nephritis among the northwest Chinese children. Eur J Intern Med 2013;24:835-8. [PMID: 23988262 DOI: 10.1016/j.ejim.2013.07.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
38 Wang CR, Tsai HW. Human hepatitis viruses-associated cutaneous and systemic vasculitis. World J Gastroenterol 2021; 27(1): 19-36 [PMID: 33505148 DOI: 10.3748/wjg.v27.i1.19] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
39 Sun L, Shan J, Cui R, Yuan W, Jiang G. Combination therapy with lamivudine and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker for hepatitis B virus-associated glomerulonephritis with mild to moderate proteinuria: a clinical review of 38 cases. Int Urol Nephrol 2017;49:1049-56. [DOI: 10.1007/s11255-017-1563-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
40 Moroni G, Ponticelli C. Secondary Membranous Nephropathy. A Narrative Review. Front Med (Lausanne) 2020;7:611317. [PMID: 33344486 DOI: 10.3389/fmed.2020.611317] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
41 Chan TM. Hepatitis B and Renal Disease. Curr Hepat Rep 2010;9:99-105. [PMID: 20461128 DOI: 10.1007/s11901-010-0042-6] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
42 Chen YC, Li CY, Tsai SJ, Chen YC. Nationwide cohort study suggests that nucleos(t)ide analogue therapy decreases dialysis risk in Taiwanese chronic kidney disease patients acquiring hepatitis B virus infection. World J Gastroenterol 2018; 24(8): 917-928 [PMID: 29491685 DOI: 10.3748/wjg.v24.i8.917] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
43 Mercadal L. [Membranous nephropathy]. Nephrol Ther 2013;9:507-17. [PMID: 24315535 DOI: 10.1016/j.nephro.2013.10.002] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
44 Chuang T, Hung C, Huang S, Lee C. Complete Remission of Nephrotic Syndrome of Hepatitis B Virus-associated Membranous Glomerulopathy After Lamivudine Monotherapy. Journal of the Formosan Medical Association 2007;106:869-73. [DOI: 10.1016/s0929-6646(08)60054-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
45 Fabrizi F, Dixit V, Martin P. Meta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritis. Aliment Pharmacol Ther. 2006;24:781-788. [PMID: 16918881 DOI: 10.1111/j.1365-2036.2006.03041.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
46 Olsen S, Brown R. Hepatitis B treatment: Lessons for the nephrologist. Kidney International 2006;70:1897-904. [DOI: 10.1038/sj.ki.5001908] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
47 Zheng H, Liu H, Hao A, Zhang M, Wang D. Association between serum Cystatin C and renal injury in patients with chronic hepatitis B. Medicine (Baltimore) 2020;99:e21551. [PMID: 32769895 DOI: 10.1097/MD.0000000000021551] [Reference Citation Analysis]
48 Rajashekar A, Perazella MA, Crowley S. Systemic Diseases with Renal Manifestations. Primary Care: Clinics in Office Practice 2008;35:297-328. [DOI: 10.1016/j.pop.2008.01.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
49 Mackelaite L, Alsauskas ZC, Ranganna K. Renal failure in patients with cirrhosis. Med Clin North Am 2009;93:855-69, viii. [PMID: 19577118 DOI: 10.1016/j.mcna.2009.03.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
50 Kong XL, Ma XJ, Su H, Xu DM. Relationship between occult hepatitis B virus infection and chronic kidney disease in a Chinese population-based cohort. Chronic Dis Transl Med 2016;2:55-60. [PMID: 29063026 DOI: 10.1016/j.cdtm.2016.07.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
51 Gupta A, Quigg RJ. Glomerular Diseases Associated With Hepatitis B and C. Advances in Chronic Kidney Disease 2015;22:343-51. [DOI: 10.1053/j.ackd.2015.06.003] [Cited by in Crossref: 46] [Cited by in F6Publishing: 28] [Article Influence: 7.7] [Reference Citation Analysis]
52 Farrell GC, Teoh NC. Management of chronic hepatitis B virus infection: a new era of disease control. Intern Med J 2006;36:100-13. [PMID: 16472264 DOI: 10.1111/j.1445-5994.2006.01027.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
53 Long JD, Rutledge SM, Sise ME. Autoimmune Kidney Diseases Associated with Chronic Viral Infections. Rheum Dis Clin North Am 2018;44:675-98. [PMID: 30274630 DOI: 10.1016/j.rdc.2018.06.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Lau C, Martin P, Bunnapradist S. Management of renal dysfunction in patients receiving a liver transplant. Clin Liver Dis 2011;15:807-20. [PMID: 22032530 DOI: 10.1016/j.cld.2011.08.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
55 Akimoto T, Otake T, Tanaka A, Takahashi H, Higashizawa T, Inoue M, Nishino K, Saito O, Isoda N, Muto S, Sugano K, Kusano E. Steroid treatment in patients with membranous nephropathy and hepatitis B virus surface antigenemia: a report of two cases. Clin Exp Nephrol 2011;15:289-93. [PMID: 21170566 DOI: 10.1007/s10157-010-0391-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
56 Mocroft A, Neuhaus J, Peters L, Ryom L, Bickel M, Grint D, Koirala J, Szymczak A, Lundgren J, Ross MJ, Wyatt CM; INSIGHT SMART Study Group., ESPRIT Study Group. Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. PLoS One 2012;7:e40245. [PMID: 22911697 DOI: 10.1371/journal.pone.0040245] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 5.3] [Reference Citation Analysis]
57 Sun IO, Hong YA, Park HS, Choi SR, Chung BH, Park CW, Yang CW, Kim YS, Choi BS. Clinical characteristics and treatment of patients with IgA nephropathy and hepatitis B surface antigen. Ren Fail 2013;35:446-51. [PMID: 23506536 DOI: 10.3109/0886022X.2013.775659] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
58 Virlogeux V, Trépo C. Extrahepatic Manifestations of Chronic Hepatitis B Infection. Curr Hepatology Rep 2018;17:156-65. [DOI: 10.1007/s11901-018-0403-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
59 Lai AS, Lai KN. Viral nephropathy. Nat Clin Pract Nephrol 2006;2:254-62. [PMID: 16932438 DOI: 10.1038/ncpneph0166] [Cited by in Crossref: 52] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
60 Ng YY, Yang WC, Lee ST. Long-term lamivudine therapy in hepatitis B-associated membranous nephropathy. Kidney Int. 2006;69:776. [PMID: 16518335 DOI: 10.1038/sj.ki.5000171] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
61 Tang S, Lai K. Hepatitis B-related membranous nephropathy should be treated with a specific anti-viral agent. Kidney International 2006;70:818. [DOI: 10.1038/sj.ki.5001586] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
62 Cacoub P, Terrier B. Hepatitis B-related autoimmune manifestations. Rheum Dis Clin North Am. 2009;35:125-137. [PMID: 19481001 DOI: 10.1016/j.rdc.2009.03.006] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 4.4] [Reference Citation Analysis]
63 Jiang L, Hu S, He M, Tian D. Estimated Glomerular Filtration Rate Increases in Chronic Hepatitis B Patients Treated With Telbivudine Monotherapy and Combination Treatment. Hepat Mon 2016;16:e32528. [PMID: 27110258 DOI: 10.5812/hepatmon.32528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
64 Hartleb M, Gutkowski K. Kidneys in chronic liver diseases. World J Gastroenterol 2012; 18(24): 3035-3049 [PMID: 22791939 DOI: 10.3748/wjg.v18.i24.3035] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
65 Vergani D, Mieli-Vergani G. Autoimmune manifestations in viral hepatitis. Semin Immunopathol. 2013;35:73-85. [PMID: 23010889 DOI: 10.1007/s00281-012-0328-6] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 4.7] [Reference Citation Analysis]